Imcyse continues patient enrolment in its Phase 1b trial in type 1 diabetes
Imcyse, a biotechnology company developing active specific therapies for the treatment of severe chronic diseases, today announces that it began…
Imcyse, a biotechnology company developing active specific therapies for the treatment of severe chronic diseases, today announces that it began…